Q-omics provides the consensus-scored CRYM profile across patient tissues and cancer cell-line models. CRYM expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CRYM is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, CRYM protein abundance shows 26,734 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, HNSC, and GBM as cancer lineages where CRYM shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CRYM — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CRYM survival associations across molecular data types. CRYM RNA expression shows survival associations in the most cancer types (23), followed by mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CRYM RNA expression–survival associations across cancer types. High CRYM expression shows unfavorable associations in UVM, THCA and MESO, but favorable associations in KIRC, ACC and LUSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CRYM RNA expression.
This table summarizes CRYM tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CRYM. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CRYM shows lower tumor expression in HNSC, BLCA, KICH, LUSC and THCA and higher tumor expression in LIHC. The HNSC box plot shows higher CRYM RNA expression in normal versus tumor tissue (log2 FC = −1.842, t-test p < 0.001).
This table shows molecular features associated with CRYM in patient tissues and cancer cell lines. In patient samples, CRYM shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, CRYM RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BLOOD_Leukemia.
